ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ADC Therapeutics S.A.NYSE: ADCT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $2.44M rose 0.9% year over year, behind the +26.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 60.1% from the prior quarter. Over 3 fiscal years it compounded at -48.5% a year.
Context
- Stock-based compensation amounted to 8.5% of revenue in FY2025, down 0.8 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +0.9% toward the trailing-twelve-month pace of +26.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.91M USD
- Year-over-year change
- +5.1%
- 4-year CAGR
- -41.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.91M | +5.1% |
| FY2024 | 2024-12-31 | 6.57M | -51.3% |
| FY2023 | 2023-12-31 | 13.5M | -73.3% |
| FY2022 | 2022-12-31 | 50.64M | -16.3% |
| FY2021 | 2021-12-31 | 60.48M | — |
Stock-Based Compensation vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's LTM Mar 2026 stock-based compensation of $12.63M is the 5th largest of the 10 companies compared; the peer median is $12.55M.
- Its year-over-year change of +26.4% is the highest of 10, against a peer median of -7.4%.
- Stock-based compensation amounts to 16.0% of revenue for ADCT, versus a peer median of 27.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $15.14M | -5.7% | +6.3% | 16.3% | |
| LTM Mar 2026 | $12.63M | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.55M | +2.5% | +2.8% | 18.0% | |
| LTM Mar 2026 | $10.98M | +14.3% | -1.3% | 592.7% | |
| LTM Mar 2026 | $5.74M | +13.3% | — | 58.0% | |
| LTM Mar 2026 | $4.71M | -8.3% | +3.5% | 31.8% | |
| LTM Mar 2026 | $2.68M | -107.0% | +13.8% | 4.2% | |
| Peer median (excluding ADCT) | $12.55M | -7.4% | +7.5% | 27.0% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Depreciation & Amortization | 2.63M | 5.74M | 3.27M | 3.28M | 1.88M |
| Deferred Income Tax | (26.05M) | 0 | 37.1M | 0 | 0 |
| Stock-Based Compensation | 60.48M | 50.64M | 13.5M | 6.57M | 6.91M |
| Change in Working Capital | (15.71M) | (49.04M) | 44.27M | 3.83M | (25.36M) |
| Accounts Receivables | (30.22M) | (42.75M) | 47.79M | 4.77M | (8.79M) |
| Inventory | (3.02M) | (9.65M) | (5.71M) | (3.73M) | (2.38M) |
| Accounts Payables | 6.8M | 310K | 3.17M | 2.46M | (9.04M) |
| Other Working Capital | 10.73M | 3.37M | (979K) | 321K | (5.15M) |
| Other Non-Cash Items | (24.7M) | 11.48M | 23.23M | 20.34M | 18.02M |
| Operating Cash Flow | (233.38M) | (138.31M) | (118.69M) | (123.84M) | (141.17M) |
| Capital Expenditures | (6.38M) | (687K) | (3.22M) | (867K) | (264K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 659K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.24M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.67M) | (687K) | (3.22M) | (867K) | 395K |
| Debt Repayment | 48.61M | (2.71M) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 60.51M | 152.46M |
| Common Stock Repurchased | 0 | (1.32M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 218.78M | 3.13M | 73.88M | 36.55M | (1.51M) |
| Financing Cash Flow | 267.39M | (897K) | 73.88M | 97.05M | 150.95M |
| Effect of Forex Changes | 6K | (208K) | 184K | (83K) | 305K |
| Net Change in Cash | 27.35M | (140.1M) | (47.84M) | (27.73M) | 10.47M |
| Free Cash Flow | (239.75M) | (139M) | (121.9M) | (124.7M) | (141.44M) |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.